Opthea’s lead biologic drug candidate, OPT-302, has been renamed ‘sozinibercept’. The nonproprietary drug name was approved by the American Medical Association’s United States Adopted

Indigenous people from around Australia have aligned to advance our understanding of genomic medicine.

Micheal Yapp has joined Optometry Australia (OA) in a new role focussed on advancing the profession, scaling up collaborative care, and supporting optometrists to

The Royal Victorian Eye and Ear Hospital (RVEEH) has opened its new Acute Ophthalmology Service (AOS), equipped with 10 consulting rooms, strategically placed near